Associated Papers
Clinical Validation of Duoseq, a Novel Assay for Clinical DNA and RNA Sequencing.
Thacker E et al.
The Journal of Molecular Diagnostics : Jmd, 2026
Leveraging genomic diagnostics for prognostics and therapeutics in pediatric acute leukemia.
Newman H et al.
Hemasphere, 2025
The role of ASXL1, SRSF2, and EZH2 mutations in chromatin dysregulation of myelodysplastic neoplasia and acute myeloid leukemia.
Yu H et al.
Leukemia, 2025
Efficacy and safety of tazemetostat, an EZH2 inhibitor, in Chinese patients with relapsed/refractory follicular lymphoma: a multicentre, single-arm, phase 2 study.
Cao J et al.
Eclinicalmedicine, 2025
A Comprehensive Guide to Achieving New York State Clinical Laboratory Evaluation Program Approval for Next-Generation Sequencing Assays.
Galbo PM et al.
The Journal of Molecular Diagnostics : Jmd, 2025
Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax/azacitidine for AML.
Ikoma Y et al.
Leukemia, 2025
Mutant EZH2 alters the epigenetic network and increases epigenetic heterogeneity in B cell lymphoma.
Griess O et al.
Plos Biology, 2025
Multisite clinical cross-validation and variant interpretation of a next generation sequencing panel for lymphoid cancer prognostication.
Sabatini PJB et al.
Journal of Clinical Pathology, 2025
Genetic subtyping by Whole Exome Sequencing across Diffuse Large B Cell Lymphoma and Plasmablastic Lymphoma.
Pomares AA et al.
Plos One, 2025
Genetic evolution of keratinocytes to cutaneous squamous cell carcinoma.
Tandukar B et al.
Biorxiv : the Preprint Server for Biology, 2024
Characterizing the Mutational Landscape of Diffuse Large B-Cell Lymphoma in a Prospective Cohort of Mexican Patients.
Candelaria M et al.
International Journal of Molecular Sciences, 2024
Multi-omics profiling of longitudinal samples reveals early genomic changes in follicular lymphoma.
Bai B et al.
Blood Cancer Journal, 2024
Thyroid papillary carcinoma combined with primary follicular lymphoma: a case report.
Xu T et al.
Diagnostic Pathology, 2024
EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition.
Romero P et al.
Nature Communications, 2024
Targeted DNA Sequencing of Cutaneous Melanoma Identifies Prognostic and Predictive Alterations.
Haugh AM et al.
Cancers, 2024
Mining cancer genomes for change-of-metabolic-function mutations.
Tu KJ et al.
Communications Biology, 2023
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C.
Chi SN et al.
Journal of the National Cancer Institute, 2023
Structural basis for inactivation of PRC2 by G-quadruplex RNA.
Song J et al.
Science (new York, N.y.), 2023
TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependence.
Wu G et al.
Science Translational Medicine, 2023
Concordance between cancer gene alterations in tumor and circulating tumor DNA correlates with poor survival in a real-world precision-medicine population.
Rosenberg S et al.
Molecular Oncology, 2023
Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMIC.
Sakthikumar S et al.
Veterinary and Comparative Oncology, 2023
Parallel testing of liquid biopsy (ctDNA) and tissue biopsy samples reveals a higher frequency of EZH2 mutations in follicular lymphoma.
Nagy Á et al.
Journal of Internal Medicine, 2023
Dynamic ctDNA Mutational Complexity in Patients with Melanoma Receiving Immunotherapy.
Fitzgerald S et al.
Molecular Diagnosis & Therapy, 2023
Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors.
Schroers-Martin JG et al.
Cancer Discovery, 2023
Characteristics and prognosis of rrDLBCL with TP53 mutations and a high-risk subgroup represented by the co-mutations of DDX3X-TP53.
Gao F et al.
Cancer Medicine, 2023
Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma.
Shen R et al.
Signal Transduction and Targeted Therapy, 2023
Waldenström macroglobulinemia whole genome reveals prolonged germinal center activity and late copy number aberrations.
Maclachlan KH et al.
Blood Advances, 2023
Rapid and Automated Semiconductor-Based Next-Generation Sequencing for Simultaneous Detection of Somatic DNA and RNA Aberrations in Myeloid Neoplasms.
Sande CM et al.
The Journal of Molecular Diagnostics : Jmd, 2023
Application of circulating tumour DNA in terms of prognosis prediction in Chinese follicular lymphoma patients.
Zhao M et al.
Frontiers in Genetics, 2023
Performance of the cobas EZH2 mutation test on clinical samples from non-Hodgkin lymphoma patients.
Shyu JY et al.
Plos One, 2023
Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia.
Arai H et al.
Biomedicines, 2022
Molecular subclusters of follicular lymphoma: a report from the United Kingdom's Haematological Malignancy Research Network.
Crouch S et al.
Blood Advances, 2022
EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment.
Martínez-Laperche C et al.
Bmc Cancer, 2022
A unifying hypothesis for PNMZL and PTFL: morphological variants with a common molecular profile.
Salmeron-Villalobos J et al.
Blood Advances, 2022
SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial.
Song Y et al.
The Lancet. Haematology, 2022
Cell-Free DNA for Genomic Analysis in Primary Mediastinal Large B-Cell Lymphoma.
Rivas-Delgado A et al.
Diagnostics (basel, Switzerland), 2022
Targeted Therapy for Adrenocortical Carcinoma: A Genomic-Based Search for Available and Emerging Options.
Hescheler DA et al.
Cancers, 2022
CancerVar: An artificial intelligence-empowered platform for clinical interpretation of somatic mutations in cancer.
Li Q et al.
Science Advances, 2022
Systematic review and meta-analysis of genomic alterations in acral melanoma.
Broit N et al.
Pigment Cell & Melanoma Research, 2022
Anaplastic thyroid cancer: genome-based search for new targeted therapy options.
Hescheler DA et al.
Endocrine Connections, 2022
Genomic Progression of Precancerous Actinic Keratosis to Squamous Cell Carcinoma.
Kim YS et al.
The Journal of Investigative Dermatology, 2022
The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanoma.
Karachaliou GS et al.
Bmc Cancer, 2022